Close Menu

Caveat Emptor

The UK's Times Online reports on the growing market of companies like 23andMe, kicking off with this straight-to-the heart statement: "Leading genetic testing companies are providing clients with widely divergent and inaccurate predictions of their chances of developing serious diseases." The author has used the services of 23andMe, DecodeMe, and British provider GeneticHealth, getting in return "contradictory assessments of the risk I faced of developing illnesses, including Alzheimer's and glaucoma, and a confused verdict on my risk of suffering heart problems."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.